Comparing the current results to its competitors, Ocean Biomedical Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.72 %, recorded in the same quarter.
Ocean Biomedical Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.22 %
Ocean Biomedical Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical companies, established biotechnology firms, and venture-backed biotechnology companies worldwide. Competitors frequently engage with research universities and medical centers to identify and develop therapeutic candidates, which may overlap with the company's inventions or technologies. Many competitors possess greater financial, technical, and human resources. Additionally, smaller and early-stage companies can be significant competitors, particularly through collaborations with larger, established companies. Competition extends to current and future product candidates from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Competitors may achieve regulatory approval more quickly or may discover, develop, license, or commercialize products before or more successfully than the company. BridgeBio is a competitor identified in company filings.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Ocean Biomedical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ocean Biomedical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
